In Vitro Antibacterial Activity of Acyl-Lysyl Oligomers against Helicobacter pylori

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2009-07-20

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/AAC.00510-09PMID 19620333PMCID PMC2764229
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Successful isolation of Helicobacter pylori after prolonged incubation from a patient with failed eradication therapy.

  2009cited by this paper
• Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.

  2009cited by this paper
• Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.

  2009cited by this paper
• Investigating the effects of positive charge and hydrophobicity on the cell selectivity, mechanism of action and anti-inflammatory activity of a Trp-rich antimicrobial peptide indolicidin.

  2009cited by this paper
• Sequential therapy for Helicobacter pylori: time to consider making the switch?

  2008cited by this paper
• The Complete Genome Sequence of Helicobacter pylori Strain G27

  2008cited by this paper
• Bacterial membranes as predictors of antimicrobial potency.

  2008cited by this paper
• Meta-analysis: Sequential Therapy Appears Superior to Standard Therapy for Helicobacter pylori Infection in Patients Naive to Treatment

  2008cited by this paper
• Impact of Self-Assembly Properties on Antibacterial Activity of Short Acyl-Lysine Oligomers

  2008cited by this paper
• Analogous oligo‐acyl‐lysines with distinct antibacterial mechanisms

  2008cited by this paper
• Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.

  2008cited by this paper
• One‐Week Once‐Daily Triple Therapy with Esomeprazole, Moxifloxacin, and Rifabutin for Eradication of Persistent Helicobacter pylori Resistant to Both Metronidazole and Clarithromycin

  2008cited by this paper
• Structure-activity relationships of antibacterial acyl-lysine oligomers.

  2008cited by this paper
• Antimicrobial Defense and Persistent Infection in Insects

  2008cited by this paper
• Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori.

  2008cited by this paper
• Evolution of Helicobacter pylori Therapy from a Meta‐analytical Perspective

  2007cited by this paper
• Sequential Therapy versus Standard Triple-Drug Therapy for Helicobacter pylori Eradication

  2007cited by this paper
• American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection

  2007cited by this paper
• Improved antimicrobial peptides based on acyl-lysine oligomers

  2007cited by this paper
• Rationale for the Design of Shortened Derivatives of the NK-lysin-derived Antimicrobial Peptide NK-2 with Improved Activity against Gram-negative Pathogens*

  2007cited by this paper
• Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy

  2007cited by this paper
• Empirical rescue therapy after Helicobacter pylori treatment failure: a 10‐year single‐centre study of 500 patients

  2007cited by this paper
• Gram-negative outer and inner membrane models: insertion of cyclic cationic lipopeptides.

  2007cited by this paper
• Antiplasmodial Activity of Lauryl-Lysine Oligomers

  2007cited by this paper
• The complete genome sequence of a chronic atrophic gastritis Helicobacter pylori strain: evolution during disease progression.

  2006cited by this paper
• Tryptophan- and arginine-rich antimicrobial peptides: structures and mechanisms of action.

  2006cited by this paper
• 2‐Week Triple Therapy for Helicobacter pylori Infection is Better Than 1‐Week in Clinical Practice: a Large Prospective Single‐Center Randomized Study

  2006cited by this paper
• Efficacy of Metronidazole as Second‐Line Drug for the Treatment of Helicobacter pylori Infection in the Japanese Population: A Multicenter Study in the Tokyo Metropolitan Area

  2006cited by this paper
• Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

  2006influential reference
• Basis for Selectivity of Cationic Antimicrobial Peptides for Bacterial Versus Mammalian Membranes*

  2005cited by this paper
• The role of cathelicidins in the innate host defenses of mammals.

  2005cited by this paper
• Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?

  2005cited by this paper
• One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication.

  2005cited by this paper
• Activation of beta-catenin by carcinogenic Helicobacter pylori.

  2005cited by this paper
• Review article: the treatment of refractory Helicobacter pylori infection

  2003cited by this paper
• A Prospective, Randomized Study of Quadruple Therapy and High‐Dose Dual Therapy for Treatment of Helicobacter Pylori Resistant to Both Metronidazole and Clarithromycin

  2003cited by this paper
• The Relationship among Previous Antimicrobial Use, Antimicrobial Resistance, and Treatment Outcomes for Helicobacter pylori Infections

  2003cited by this paper
• Differential Regulation of Amidase- and Formamidase-mediated Ammonia Production by the Helicobacter pylori Fur Repressor*

  2003cited by this paper
• Antimicrobial peptides from hylid and ranin frogs originated from a 150-million-year-old ancestral precursor with a conserved signal peptide but a hypermutable antimicrobial domain.

  2003cited by this paper
• Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima.

  2002cited by this paper
• Antibacterial Properties of Dermaseptin S4 Derivatives with In Vivo Activity

  2002cited by this paper
• Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy

  2002cited by this paper
• Tryptophan-rich antimicrobial peptides: comparative properties and membrane interactions.

  2002cited by this paper
• Mechanisms of acid resistance due to the urease system of Helicobacter pylori.

  2002cited by this paper
• Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia

  2001cited by this paper
• A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole

  2001cited by this paper
• European Multicentre Survey of in Vitro Antimicrobial Resistance in Helicobacter pylori

  2001cited by this paper
• Frame-shift mutations in NAD(P)H flavin oxidoreductase encoding gene (frxA) from metronidazole resistant Helicobacter pylori ATCC43504 and its involvement in metronidazole resistance.

  2000cited by this paper
• Secondary Resistance Among 554 Isolates of Helicobacter pylori After Failure of Therapy

  2000cited by this paper
• High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong

  2000cited by this paper
• Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta‐analysis of eradication of Helicobacter pylori

  2000cited by this paper
• Two‐week dual vs. one‐week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial

  1999cited by this paper
• Effectiveness of Helicobacter pylori therapies in a clinical practice setting.

  1999cited by this paper
• Diversity of antimicrobial peptides and their mechanisms of action.

  1999cited by this paper
• Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori

  1999cited by this paper
• Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides.

  1999cited by this paper
• Pore formation by nisin involves translocation of its C-terminal part across the membrane.

  1998cited by this paper
• The mode of action of metronidazole in Helicobacter pylori: futile cycling or reduction?

  1998cited by this paper
• [Seven-day omeprazole, clarithromycin, and amoxicillin for the therapy of Helicobacter pylori infection].

  1998cited by this paper
• Absence of a post-antibiotic effect (PAE) of beta-lactams against Helicobacter pylori NCTC 11637.

  1998cited by this paper
• Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen‐insensitive NADPH nitroreductase

  1998cited by this paper
• Guidelines for the management of Helicobacter pylori infection

  1998cited by this paper
• The role of internal urease in acid resistance of Helicobacter pylori.

  1998cited by this paper
• The Lipopolysaccharide of Bordetella bronchiseptica Acts as a Protective Shield against Antimicrobial Peptides

  1998influential reference
• The complete genome sequence of the gastric pathogen Helicobacter pylori

  1997cited by this paper
• Pharmacodynamic effects of antibiotics and acid pump inhibitors on Helicobacter pylori

  1997cited by this paper
• A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain.

  1997cited by this paper
• Metabolic activities of metronidazole-sensitive and -resistant strains of Helicobacter pylori: repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance

  1996cited by this paper
• 4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection.

  1996cited by this paper
• In vitro killing of penicillin-susceptible, -intermediate, and -resistant strains of Streptococcus pneumoniae by cefotaxime, ceftriaxone, and ceftizoxime: a comparison of bactericidal and inhibitory activity with achievable CSF levels.

  1995cited by this paper
• Helicobacter pylori infection and gastric lymphoma.

  1994cited by this paper
• Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes

  1994cited by this paper
• Helicobacter pylori Infection and the Risk for Duodenal and Gastric Ulceration

  1994cited by this paper
• Inducible type of erythromycin resistance among group B streptococci isolated in Greece.

  1993cited by this paper
• The post-antibiotic effect of antimicrobial combinations in a neutropenic murine thigh infection model.

  1993cited by this paper
• Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii.

  1991cited by this paper
• Mode of action of the lanthionine-containing peptide antibiotics duramycin, duramycin B and C, and cinnamycin as indirect inhibitors of phospholipase A2.

  1991cited by this paper
• Characterization of urease from Campylobacter pylori

  1988cited by this paper
• Evaluation of the bactericidal activity of beta-lactam antibiotics on slowly growing bacteria cultured in the chemostat

  1986cited by this paper
• Rapid urea hydrolysis by gastric Campylobacters.

  1985cited by this paper
• Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.

  1984cited by this paper
• Generation times of Proteus mirabilis and Escherichia coli in experimental infections.

  1973cited by this paper
• The true division and death rates of Salmonella typhimurium in the mouse spleen determined with superinfecting phage P22.

  1968cited by this paper
• Activation of (cid:1) -catenin by carcinogenic Helicobacter pylori

  year unknowncited by this paper

• Vitamin B6 inhibits activity of Helicobacter pylori adenylosuccinate synthetase and growth of reference and clinical, antibiotic-resistant H. pylori strains

  2024influential citation
• Selected Antimicrobial Peptides Inhibit In Vitro Growth of Campylobacter spp.

  2022influential citation
• In vitro activity of neem (Azadirachta indica) oil extract against Helicobacter pylori.

  2019cites this paper
• Unveiling the Crucial Role of Type IV Secretion System and Motility of Helicobacter pylori in IL-1β Production via NLRP3 Inflammasome Activation in Neutrophils

  2019cites this paper
• Anti-Helicobacter pylori activity of ethoxzolamide

  2019cites this paper
• Identification and characterization of two novel cathelicidins from the frog Odorrana livida

  2018cites this paper
• β-Defensins in the Fight against Helicobacter pylori

  2017cites this paper
• Advances in Development of Antimicrobial Peptidomimetics as Potential Drugs

  2017cites this paper
• Efficacy of the antimicrobial peptide TP4 against Helicobacter pylori infection: in vitro membrane perturbation via micellization and in vivo suppression of host immune responses in a mouse model

  2015cites this paper
• An insight into cochleates, a potential drug delivery system

  2015cites this paper
• The effect of LfcinB9 on human ovarian cancer cell SK‐OV‐3 is mediated by inducing apoptosis

  2014cites this paper
• Nontraditional therapies to treat Helicobacter pylori infection

  2014cites this paper
• Tolerance of yeast biofilm cells towards systemic antifungals

  2014cites this paper
• BF-30 effectively inhibits ciprofloxacin-resistant bacteria in vitro and in a rat model of vaginosis

  2014cites this paper
• Controversy over Anti-Helicobacter pylori ! erapy

  2013cites this paper
• In Vitro Characterization of the Anti-Bacterial Activity of SQ109 against Helicobacter pylori

  2013cites this paper
• The Synthetic Amphipathic Peptidomimetic LTX109 Is a Potent Fungicide That Disturbs Plasma Membrane Integrity in a Sphingolipid Dependent Manner

  2013cites this paper
• BF-30 effectively inhibits ciprofloxacin-resistant bacteria in vitro and in a rat model of vaginosis

  2013influential citation
• The controversy over anti-Helicobacter pylori therapy.

  2012cites this paper
• Recombinant Expression of a Putative Amidase Cloned from the Genome of Listeria monocytogenes that Lyses the Bacterium and its Monolayer in Conjunction with a Protease

  2012cites this paper
• The Oligo-Acyl Lysyl Antimicrobial Peptide C12K-2β12 Exhibits a Dual Mechanism of Action and Demonstrates Strong In Vivo Efficacy against Helicobacter pylori

  2011influential citation
• Recombinant expression of two bacteriophage proteins that lyse clostridium perfringens and share identical sequences in the C-terminal cell wall binding domain of the molecules but are dissimilar in their N-terminal active domains.

  2010cites this paper
• Experimental Conditions That Enhance Potency of an Antibacterial Oligo-Acyl-Lysyl

  2010influential citation